Alexion takes option to acquire Caelum's amyloidosis program

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) purchased an equity stake in Caelum Biosciences Inc. (New York, N.Y.) and an obtained an option to acquire the company, which is developing a mAb to treat amyloid light-chain (AL) amyloidosis.

The deal gives Alexion a path to gain rights to CAEL-101, Caelum's sole asset. Fortress Biotech Inc. (NASDAQ:FBIO), which owns about 40% of Caelum's equity, gained $0.59 (40%) to $2.07 on Thursday...